PHOSPHOTOPE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PHOSPHOTOPE (PHOSPHOTOPE).
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
| Metabolism | Not metabolized; excreted unchanged in feces. |
| Excretion | Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%. |
| Half-life | Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients. |
| Protein binding | 92-96% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Intravenous: 100% (only route used); oral: <5% due to extensive first-pass metabolism. |
| Onset of Action | Intravenous: 5-10 minutes for full clinical effect. |
| Duration of Action | Duration: 4-6 hours after single IV dose; clinical effect persists up to 12 hours due to extensive tissue binding. |
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required for renal impairment. However, use with caution in patients with severe renal dysfunction due to potential for accumulation of active metabolites. |
| Liver impairment | No specific dose adjustment provided for hepatic impairment. Use caution in severe hepatic dysfunction. |
| Pediatric use | 0.02-0.2 mcg/kg/min intravenous infusion, titrated to effect. Maximum dose: 1 mcg/kg/min. |
| Geriatric use | Start at lower end of dosing range (10 mcg/kg) due to increased sensitivity and potential for arrhythmias. Monitor closely for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PHOSPHOTOPE (PHOSPHOTOPE).
| Breastfeeding | Technetium-99m is excreted into breast milk. The M/P ratio is not well established; however, after administration of 99mTc-labeled compounds, the radioactivity in milk can be detected. To minimize infant exposure, breastfeeding should be interrupted for at least 24-48 hours after administration, and the milk should be expressed and discarded during this period. |
| Teratogenic Risk | PHOSPHOTOPE (technetium-99m-labeled phosphate compounds) is a diagnostic radiopharmaceutical. The radiation exposure to the fetus depends on the administered activity and gestational stage. Potential fetal risks include growth retardation, malformations, and carcinogenesis, particularly during organogenesis (weeks 2-8) and the early fetal period. The risk is dose-dependent; low administered activities used for imaging are generally considered to pose a negligible risk, but the procedure should be avoided unless the maternal benefit outweighs the risk. |
■ FDA Black Box Warning
None listed.
| Serious Effects |
["Hypersensitivity to phosphotope or any component.","Hypercalcemia."]
| Precautions | ["May cause hypercalcemia; monitor serum calcium levels.","Use with caution in patients with gastrointestinal disorders."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring beyond standard radiation safety precautions. Ensure adequate hydration to promote radionuclide excretion. In pregnant patients, confirm that the procedure is necessary and use the lowest possible radioactivity. Fetal dose estimation should be performed by a medical physicist. |
| Fertility Effects | No direct evidence of adverse effects on fertility from diagnostic doses of technetium-99m-labeled compounds. However, radiation exposure to gonads may theoretically cause temporary or permanent effects, but at diagnostic levels, the risk is minimal. |